RecruitingNot ApplicableNCT05809609

Glutamate Emotion Memory Study

Does Modulation of Glutamate Transmission in the Brain Using a Sub-anaesthetic Dose of Ketamine Affect Autobiographical Memory, Emotional Processing and Decision-making in Treatment-resistant Depression?


Sponsor

University of Oxford

Enrollment

60 participants

Start Date

Jul 1, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

Clinical depression often includes a pessimistic view of things which have happened in the past and an impairment in the ability to experience pleasure or looking forward to things. A licensed drug called ketamine affects the levels of glutamate, a chemical messenger in the brain, and has been used as a treatment particularly for depression which hasn't got better with other types of medication. Glutamate plays a role in learning and memory so the investigators are interested in understanding how ketamine can affect how people with depression remember past negative and positive memories and how they experience reward. The investigators are conducting a study in depressed participants who did not improve with the standard antidepressant treatment to expand our understanding on how ketamine can influence memory, the way people understand emotions and learn from rewards and punishments. Study participants will undergo medical and psychiatric health screening, drug administration (ketamine or saline), questionnaires and computer tasks before and after the administration of the study drug, and an MRI scan after administration of the drug. MRI is a type of brain scan that allows us to see how the brain responds during for example memories of things which have happened in the past. This project will help us understand how NMDA antagonists may work in depression.


Eligibility

Min Age: 20 YearsMax Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This study is exploring how the brain chemical glutamate affects emotional memory processing in people with treatment-resistant depression — specifically those who haven't responded adequately to antidepressants. **You may be eligible if...** - You have a current diagnosis of Major Depressive Disorder (moderate to severe episode) - Your depression has not adequately improved after trying at least one (but no more than three) antidepressants - You are fluent in English and able to complete computer-based tasks - You are registered with a GP who can be informed of your participation **You may NOT be eligible if...** - You have responded well to antidepressants - You have a history of psychosis or other conditions that may interfere with the study - You are not fluent in English Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGKetamine Hydrochloride

Ketamine is a high trapping NMDA receptor antagonist which has rapid and reliable antidepressant effects in patients with major depressive disorder (MDD) who fail to respond to at least two antidepressant trials of adequate dose and duration.

OTHERNo intervention (placebo)

Placebo injection (0.9% sodium chloride)


Locations(1)

Department of Psychiatry, University of Oxford

Oxford, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05809609


Related Trials